Skip to main content
OpenTrials
Completed

NCT Number: NCT04889391

Study of Radiolabeled Danicopan in Healthy Male Participants

This was an open-label study to evaluate the absorption, distribution, metabolism, and excretion of radioactivity in healthy male participants following a single 150-milligram (mg) oral dose of carbon-14 ([14C])-ACH-014447 ([14C])-danicopan) containing approximately 100 microcuries (µCi) of [14C].

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Clinical Trial Site

Auckland, New Zealand

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Healthy was defined as having no clinical relevant abnormalities identified by a detailed medical history, physical exam, blood pressure and pulse rate measurements, 12-lead electrocardiogram, and clinical laboratory tests.
  • Body mass index of ≥ 18 and ≤ 30 kilograms (kg)/meter squared and weight of ≥ 50 kg and ≤ 100 kg.
  • Regular daily bowel movements (that is, production of at least 1 stool per day).
  • Non-smoker or ex-smoker who had not used tobacco or nicotine products for ≥ 3 months prior to screening.

Key Exclusion Criteria:

  • History or clinically relevant evidence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  • History of conditions or procedures possibly affecting drug absorption or excretion. A history of appendectomy, cholecystectomy, and hernia repair was allowed if they were not associated with complications.
  • Active bacterial infection or clinically significant active viral infection, a body temperature > 38°Celcius, or other evidence of infection on Day 1, or with a history of febrile illness within 7 days prior to Day 1.
  • Healthy participants who had been exposed to significant radiation levels of > 5 millisieverts in the last year prior to screening.
  • Clinically significant laboratory abnormalities at screening or Day -1, as well as absolute neutrophil counts, platelets, and hemoglobin outside of reference ranges.

Treatment and study plan

[14C]-Danicopan

Drug

Liquid-filled capsules.

Other names: ALXN2040, ACH-014447, ACH-4471, ACH4471, 4471

Primary outcomes

  1. Mean Cumulative Percentages Of Total Radioactivity Recovered In Urine And Feces Following A Single Oral Dose Of [14C]-Danicopan

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

  2. Whole Blood And Plasma Pharmacokinetics (PK) Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Area Under The Concentration-time Curve From Time 0 To The Time Of Last Quantifiable Concentration (AUC0-t)

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

  3. Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Area Under The Concentration-time Curve Extrapolated to Infinity (AUC0-inf)

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

  4. Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Maximum Observed Concentration (Cmax)

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

  5. Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Time To Maximum Observed Concentration (Tmax)

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

  6. Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: AUC0-t

    Time frame: Up to 96 hours postdose

  7. Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: AUC0-inf

    Time frame: Up to 96 hours postdose

  8. Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: Cmax

    Time frame: Up to 96 hours postdose

  9. Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: Tmax

    Time frame: Up to 96 hours postdose

  10. [14C]-Danicopan Metabolites In Plasma, Urine, And Feces

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

Secondary outcomes

  1. Percentage Of Total Radioactivity Detected For Each [14C]-Danicopan Metabolite in Plasma, Urine, And Feces

    Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period

    [14C]-Danicopan metabolic profiling in plasma, urine, and feces was performed in samples containing sufficient amounts of radioactivity. The percent of dose represented by each of the metabolites was calculated using the radioactivity concentration equivalent data combined with the metabolic profiling data. The percentage of each identified metabolite to total radioactivity in plasma was estimated based on plasma metabolic profiling data.

  2. Incidence Of Treatment-emergent Adverse Events

    Time frame: Day 1 through Day 10

Sponsors and collaborators

Lead sponsor

Alexion Pharmaceuticals, Inc.

Industry

Collaborators

  • Achillion, a wholly owned subsidiary of Alexion

Registry information

Official study title

A Phase I, Open-Label, Single Dose ADME Study of 14C-ACH-0144471 in Healthy Male Subjects

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
May 17, 2021
Registry last updated
May 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.